Clinical Trials Logo

Clinical Trial Summary

This is a randomized, multicenter, double-blind, placebo-controlled, Phase 2-3 study of patients diagnosed with advanced unresectable dedifferentiated liposarcoma. Approximately 342 total patients will be randomized to study treatment (selinexor or placebo).


Clinical Trial Description

In the Phase 2 portion of the study, 57 patients were randomized to selinexor (60 mg) or placebo at a 1:1 allocation ratio. In the Phase 3 portion of the study, approximately 285 patients will be randomized to selinexor (60 mg) or placebo with a 2:1 allocation ratio. Patients who progress during the blinded portion of the study will be unblinded and if receiving: - placebo, may cross over to open-label selinexor (60mg twice-weekly) - selinexor, will be withdrawn from further treatment and followed for survival Study treatment will be given twice-weekly on Day 1 and Day 3 during Weeks 1-6 of each six-week (42 day) cycle until disease progression or intolerability. Treatment will continue until one or more of the following occurs: - Disease progression, as defined by RECIST v1.1 Response Criteria - Clinical progression, as determined by the treating physician - Unacceptable adverse events (AEs) or failure to tolerate study treatment - Patient withdrawal - Patient discontinuation due to non-compliance ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02606461
Study type Interventional
Source Karyopharm Therapeutics Inc
Contact
Status Completed
Phase Phase 2/Phase 3
Start date January 4, 2016
Completion date October 26, 2021

See also
  Status Clinical Trial Phase
Active, not recruiting NCT03307616 - Nivolumab With and Without Ipilimumab and Radiation Therapy in Treating Patients With Recurrent or Resectable Undifferentiated Pleomorphic Sarcoma or Dedifferentiated Liposarcoma Before Surgery Phase 2
Completed NCT01913652 - Ph II Cabazitaxel DD Liposarcoma Phase 2
Not yet recruiting NCT06389799 - A Phase 2, Open Label Study of PEmigatinib and REtifanlimab in Advanced Dedifferentiated LIposarcoma (PERELI) Phase 2
Recruiting NCT05886634 - A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma Phase 2
Completed NCT06115681 - Real-world Study of Dedifferentiated Liposarcoma Patients in China
Active, not recruiting NCT02846987 - Study of Abemaciclib in Dedifferentiated Liposarcoma Phase 2
Terminated NCT04979442 - Treatment of Milademetan Versus Trabectedin in Patient With Dedifferentiated Liposarcoma Phase 3
Active, not recruiting NCT04242238 - Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas Phase 1
Withdrawn NCT00969917 - Study Evaluating the Efficacy and Safety of IPI 504 in Patients With Advanced Dedifferentiated Liposarcoma Phase 2
Active, not recruiting NCT03651375 - Hypofractionated Radiotherapy With Sequential Chemotherapy in Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall Phase 2
Terminated NCT03604783 - Phase 1, First-in-human Study of Oral TP-1287 in Patients With Advanced Solid Tumors Phase 1
Not yet recruiting NCT05496569 - TQB3616 Capsules in the Treatment of Dedifferentiated Liposarcoma Phase 2